{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:21:59Z","timestamp":1795119719824,"version":"4.10.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-0812-x","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T08:07:02Z","timestamp":1515744422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The use of eculizumab in gemcitabine induced thrombotic microangiopathy"],"prefix":"10.1186","volume":"19","author":[{"given":"Vinod","family":"Krishnappa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikoo","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthavat","family":"Tanphaichitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3892-8376","authenticated-orcid":false,"given":"Rupesh","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"issue":"5","key":"812_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jca.20213","volume":"24","author":"EM Gore","year":"2009","unstructured":"Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher. 2009;24(5):209\u201314.","journal-title":"J Clin Apher"},{"issue":"8","key":"812_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","volume":"347","author":"JL Moake","year":"2002","unstructured":"Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589\u2013600.","journal-title":"N Engl J Med"},{"issue":"4","key":"812_CR3","first-page":"369","volume":"6","author":"MW Saif","year":"2005","unstructured":"Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP : Journal of the pancreas. 2005;6(4):369\u201374.","journal-title":"JOP : Journal of the pancreas"},{"issue":"3\u20134","key":"812_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000174075","volume":"19","author":"W Proesmans","year":"1996","unstructured":"Proesmans W. Typical and atypical hemolytic uremic syndrome. Kidney Blood Press Res. 1996;19(3\u20134):205\u20138.","journal-title":"Kidney Blood Press Res"},{"key":"812_CR5","doi-asserted-by":"crossref","unstructured":"Tumma A. Atypical haemolytic uraemic syndrome associated with cabazitaxel in advanced prostate cancer. Medical Case Reports. 2016;2(3)","DOI":"10.21767\/2471-8041.100030"},{"key":"812_CR6","doi-asserted-by":"crossref","unstructured":"Kavanagh D, Goodship TH, Richards A: Atypical haemolytic uraemic syndrome. Br Med Bull 2006, 77-78:5\u201322.","DOI":"10.1093\/bmb\/ldl004"},{"key":"812_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fped.2014.00097","volume":"2","author":"J Hofer","year":"2014","unstructured":"Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Frontiers in pediatrics. 2014;2:97.","journal-title":"Frontiers in pediatrics"},{"issue":"1","key":"812_CR8","first-page":"E30","volume":"5","author":"O Al Ustwani","year":"2014","unstructured":"Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P, Iyer R. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. Journal of gastrointestinal oncology. 2014;5(1):E30\u20133.","journal-title":"Journal of gastrointestinal oncology"},{"issue":"1","key":"812_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF00873232","volume":"12","author":"ES Casper","year":"1994","unstructured":"Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG, Phase II. Trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investig New Drugs. 1994;12(1):29\u201334.","journal-title":"Investig New Drugs"},{"issue":"5","key":"812_CR10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1159\/000013525","volume":"19","author":"K Lhotta","year":"1999","unstructured":"Lhotta K, Kuhr T, Rumpelt HJ, Woll E, Thaler J, Konig P. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. Am J Nephrol. 1999;19(5):590\u20133.","journal-title":"Am J Nephrol"},{"issue":"1","key":"812_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ygyno.2004.12.027","volume":"97","author":"SN Lewin","year":"2005","unstructured":"Lewin SN, Mutch DG, Whitcomb BP, Liapis H, Herzog TJ. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol. 2005;97(1):228\u201333.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"812_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00277-004-0938-8","volume":"84","author":"S Muller","year":"2005","unstructured":"Muller S, Schutt P, Bojko P, Nowrousian MR, Hense J, Seeber S, Moritz T. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol. 2005;84(2):110\u20134.","journal-title":"Ann Hematol"},{"key":"812_CR13","doi-asserted-by":"crossref","unstructured":"Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, Brocheriou I, Bourry E, Karie S, Saeb S et al: Gemcitabine-induced thrombotic microangiopathy: a systematic review. In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Volume 21, edn. England; 2006: 3038\u20133045.","DOI":"10.1093\/ndt\/gfl507"},{"key":"812_CR14","doi-asserted-by":"crossref","unstructured":"Ruiz I, Del Valle J, Gomez A: Gemcitabine and haemolytic-uraemic syndrome. In: Annals of oncology : official journal of the European Society for Medical Oncology\/ESMO. Volume 15, edn. England; 2004: 1575\u20131576.","DOI":"10.1093\/annonc\/mdh397"},{"issue":"1","key":"812_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/028418698423267","volume":"37","author":"M van der Heijden","year":"1998","unstructured":"van der Heijden M, Ackland SP, Deveridge S. Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy--a case report and review of the literature. Acta oncologica (Stockholm, Sweden). 1998;37(1):107\u20139.","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"issue":"6","key":"812_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4065\/74.6.570","volume":"74","author":"C Porta","year":"1999","unstructured":"Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc. 1999;74(6):570\u20134.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"812_CR17","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.35758","volume":"40","author":"RB Walter","year":"2002","unstructured":"Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2002;40(4):E16.","journal-title":"American journal of kidney diseases : the official journal of the National Kidney Foundation"},{"key":"812_CR18","first-page":"57","volume":"8","author":"VC Kok","year":"2014","unstructured":"Kok VC, Wu SC, Lee CK. Successful remission of hemolytic-uremic syndrome during the third-line weekly gemcitabine for metastatic breast cancer. Breast cancer : basic and clinical research. 2014;8:57\u20139.","journal-title":"Breast cancer : basic and clinical research"},{"issue":"6","key":"812_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/00001813-199907000-00004","volume":"10","author":"M Gross","year":"1999","unstructured":"Gross M, Hiesse C, Kriaa F, Goldwasser F. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. Anti-Cancer Drugs. 1999;10(6):533\u20136.","journal-title":"Anti-Cancer Drugs"},{"issue":"9","key":"812_CR20","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","volume":"85","author":"MC Fung","year":"1999","unstructured":"Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999;85(9):2023\u201332.","journal-title":"Cancer"},{"issue":"9","key":"812_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00277-005-1049-x","volume":"84","author":"C Pfister","year":"2005","unstructured":"Pfister C. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol. 2005;84(9):621\u20132.","journal-title":"Ann Hematol"},{"issue":"3","key":"812_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","volume":"33","author":"CD Flombaum","year":"1999","unstructured":"Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis. 1999;33(3):555\u201362.","journal-title":"Am J Kidney Dis"},{"key":"812_CR23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1874303X01407010091","volume":"9","author":"A Asif","year":"2014","unstructured":"Asif A, Vachharajani T, Salman L, Nayer A. A Simplified Approach to the Diagnosis of Atypical HUS: Clinical Considerations and Practical Implications. The Open Urology & Nephrology Journal. 2014;9:91\u20134.","journal-title":"The Open Urology & Nephrology Journal"},{"key":"812_CR24","first-page":"649","volume":"10","author":"K Govind Babu","year":"2016","unstructured":"Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016;10:649.","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"812_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","volume":"64","author":"A Bharthuar","year":"2009","unstructured":"Bharthuar A, Egloff L, Becker J, George M, Lohr JW, Deeb G, Iyer RV. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother Pharmacol. 2009;64(1):177\u201381.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"812_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00280-010-1258-4","volume":"65","author":"BL Gourley","year":"2010","unstructured":"Gourley BL, Mesa H, Gupta P. Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (TTP\/HUS) with rituximab. Cancer Chemother Pharmacol. 2010;65(5):1001\u20134.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"812_CR27","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","volume":"26","author":"M Weitz","year":"2011","unstructured":"Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatric nephrology (Berlin, Germany). 2011;26(8):1325\u20139.","journal-title":"Pediatric nephrology (Berlin, Germany)"},{"key":"812_CR28","doi-asserted-by":"crossref","unstructured":"Starck M, Wendtner CM. Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol. 2013;","DOI":"10.1111\/bjh.12686"},{"issue":"10","key":"812_CR29","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.revmed.2015.12.027","volume":"37","author":"T Rogier","year":"2016","unstructured":"Rogier T, Gerfaud-Valentin M, Pouteil-Noble C, Taleb A, Guillet M, Noel A, Broussolle C, Seve P. Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report. La Revue de Med Int. 2016;37(10):701\u20134.","journal-title":"La Revue de Med Int"},{"key":"812_CR30","doi-asserted-by":"crossref","unstructured":"Turner JL, Reardon J, Bekaii-Saab T, Cataland SR, Arango MJ. Gemcitabine-associated thrombotic Microangiopathy: response to complement inhibition and Reinitiation of gemcitabine. Clin Colorectal Cancer. 2016;","DOI":"10.1016\/j.clcc.2016.09.004"},{"key":"812_CR31","doi-asserted-by":"crossref","unstructured":"Lopez Rubio ME, Rodado Martinez R, Illescas ML, Mateo Bosch E, Martinez Diaz M, de la Vara Inesta L, Cabezuelo B, Morales Albuja ME, Lucas Guillen E, Jimeno Garcia L: Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports. Clinical nephrology 2017;87(2017)(2):100\u2013106.","DOI":"10.5414\/CN108838"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T05:11:30Z","timestamp":1570597890000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-0812-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-0812-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"12 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained from the patient for this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"9"}}